Astex Pharmaceuticals

SuperGen Reports Third Quarter Financial Results Nine-month revenue up 54 percent to $4.7 million SAN RAMON, Calif., Nov. 10 /PRNewswire/ -- SuperGen Inc. (Nasdaq: SUPG; SUPGZ) today reported financial results for the third quarter ended September 30, 2000. Revenue for the 2000 third quarter was $793,000, compared with revenue of $736,000 for the comparable period in 1999. The net loss for the 2000 third quarter was $9,893,000, or $0.30 per share, a decrease of 46 percent, compared with a net loss of $18,214,000, or $0.78 per share, for the same period last year. Revenue for the nine months ended September 30, 2000 was $4,743,000, an increase of 54 percent, compared with revenue of $3,076,000 for the same period in 1999. The net loss for the nine months ended September 30, 2000, was $25,340,000, or $0.81 per share. For the nine months ended September 30, 1999, the company reported a net loss of $28,380,000, or $1.29 per share. Included in the net losses for the three months and nine months ended September 30, 2000 and 1999 were one time non-cash charges related to the acquisition of in-process research and development of $1,585,000 and $10,850,000, respectively. Research and development (R&D) expense increased 102 percent for the 2000 third quarter and 111 percent for the nine months, compared to the same two periods last year. ``The increase in R&D can be attributed to an extremely aggressive clinical research program,'' said Dr. Joseph Rubinfeld, chairman and chief executive officer of SuperGen. ``We currently have over 25 different clinical trials underway in a variety of compounds and indications. Looking forward, we will soon initiate three additional Phase III clinical studies for Nipent®, Avicine(TM) and decitabine. ``Our multi-arm Phase III clinical study of rubitecan is the largest clinical trial ever undertaken for pancreatic cancer,'' added Dr. Rubinfeld. ``We now have more than 1,400 patients enrolled in the study, and we expect that enrollment in one of the three arms of the trial will be completed in the very near-term. Data from any of the three arms can independently be used in the filing of a New Drug Application.'' Other significant announcements during the course of the third quarter included data presented at the Leukemia 2000 conference showing that the company's anticancer compound rubitecan has significant activity in several hematologic malignancies, including chronic myeloid leukemia, chronic myelomonocytic leukemia and myelodysplastic syndrome; discussions about the potential of Nipent in graft-versus-host disease and other hematologic malignancies at the Leukemia 2000 conference; and, the authorization by the board of directors for a repurchase program to buy back up to one million shares of common stock.

Bilanz ebenfalls +/- 0. Langsam wird auch ABGX wieder interessant:

aber durchaus im Rahmen des allgemeinen Trends bei den Biotechs geblieben. Wobei das Quartalsergebnis kaum ins Gewicht fällt, da SUPG erst ein Medikament vertreibt und damit Gewinne erzielt, dementsprechend Umsatz- und Ertragszahlen nicht sehr aussagekräftig sind. Inwieweit der Verlust auf gestiegene Kosten im Forschungsbereich zurückzuführen ist, was ja durchaus positiv zu sehen wäre, lässt sich aus der Kurzmeldung auch nicht ersehen. Ich bin jedenfalls mit einer kleinen Position seit einer Woche dabei - bis jetzt +/- 0. Gruß Dampf

Monday, November 13, 2000 SUPG misses by a penny --9:36 am - By Michael Baron SuperGen (SUPG: news, msgs) is sliding $1.98, or 9.2 percent, to $19.50, after the San Ramon, Calif., pharmaceutical firm reported a wider-than-expected loss in the third quarter. SuperGen lost $9.8 million, or 30 cents a share, in the latest three months, narrower than last year's loss of $18.2 million, or 78 cents a share, and a penny wider than First Call's average loss estimate. Revenue for the quarter was $793,000, slightly higher than $736,000 last yea